<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Parenteral anticoagulation in ambulatory patients with cancer - Akl, EA - 2017 | Cochrane Library</title> <meta content="Parenteral anticoagulation in ambulatory patients with cancer - Akl, EA - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006652.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Parenteral anticoagulation in ambulatory patients with cancer - Akl, EA - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006652.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006652.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Parenteral anticoagulation in ambulatory patients with cancer" name="citation_title"/> <meta content="Elie A Akl" name="citation_author"/> <meta content="American University of Beirut Medical Center" name="citation_author_institution"/> <meta content="ea32@aub.edu.lb" name="citation_author_email"/> <meta content="Lara A Kahale" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Maram B Hakoum" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Charbel F Matar" name="citation_author"/> <meta content="American University of Beirut Medical Center" name="citation_author_institution"/> <meta content="Francesca Sperati" name="citation_author"/> <meta content="Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Maddalena Barba" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Victor ED Yosuico" name="citation_author"/> <meta content="Buffalo Medical Group" name="citation_author_institution"/> <meta content="Irene Terrenato" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Anneliese Synnot" name="citation_author"/> <meta content="Holger Schünemann" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006652.pub5" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/09/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006652.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006652.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006652.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [*administration &amp; dosage, adverse effects]; Cause of Death; Hemorrhage [chemically induced, epidemiology]; Heparin [*administration &amp; dosage, adverse effects]; Heparin, Low-Molecular-Weight [administration &amp; dosage]; Neoplasms [*mortality]; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Venous Thromboembolism [epidemiology, *prevention &amp; control]; Warfarin [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006652.pub5&amp;doi=10.1002/14651858.CD006652.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="6nHUP32m";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006652\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006652\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","ms","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006652.pub5",title:"Parenteral anticoagulation in ambulatory patients with cancer",firstPublishedDate:"Sep 11, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006652.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006652.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006652.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006652.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006652.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006652.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006652.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006652.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006652.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006652.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4181 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006652.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/appendices#CD006652-sec-0078"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/table_n/CD006652StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/table_n/CD006652StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Parenteral anticoagulation in ambulatory patients with cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Elie A Akl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0005">Lara A Kahale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0006">Maram B Hakoum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0007">Charbel F Matar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0008">Francesca Sperati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0009">Maddalena Barba</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0010">Victor ED Yosuico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0011">Irene Terrenato</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0012">Anneliese Synnot</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information#CD006652-cr-0013">Holger Schünemann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information/en#CD006652-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 September 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006652.pub5">https://doi.org/10.1002/14651858.CD006652.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006652-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006652-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006652-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006652-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006652-abs-0006">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006652-abs-0001" lang="en"> <section id="CD006652-sec-0001"> <h3 class="title" id="CD006652-sec-0001">Background</h3> <p>Anticoagulation may improve survival in patients with cancer through a speculated anti‐tumour effect, in addition to the antithrombotic effect, although may increase the risk of bleeding. </p> </section> <section id="CD006652-sec-0002"> <h3 class="title" id="CD006652-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of parenteral anticoagulants in ambulatory patients with cancer who, typically, are undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. </p> </section> <section id="CD006652-sec-0003"> <h3 class="title" id="CD006652-sec-0003">Search methods</h3> <p>A comprehensive search included (1) a major electronic search (February 2016) of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 1), MEDLINE (1946 to February 2016; accessed via OVID) and Embase (1980 to February 2016; accessed via OVID); (2) handsearching of conference proceedings; (3) checking of references of included studies; (4) use of the 'related citation' feature in PubMed and (5) a search for ongoing studies in trial registries. As part of the living systematic review approach, we are running searches continually and we will incorporate new evidence rapidly after it is identified. This update of the systematic review is based on the findings of a literature search conducted on 14 August 2017. </p> </section> <section id="CD006652-sec-0004"> <h3 class="title" id="CD006652-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) assessing the benefits and harms of parenteral anticoagulation in ambulatory patients with cancer. Typically, these patients are undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. </p> </section> <section id="CD006652-sec-0005"> <h3 class="title" id="CD006652-sec-0005">Data collection and analysis</h3> <p>Using a standardized form we extracted data in duplicate on study design, participants, interventions outcomes of interest, and risk of bias. Outcomes of interested included all‐cause mortality, symptomatic venous thromboembolism (VTE), symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), major bleeding, minor bleeding, and quality of life. We assessed the certainty of evidence for each outcome using the GRADE approach (GRADE handbook [GRADE handbook]). </p> </section> <section id="CD006652-sec-0006"> <h3 class="title" id="CD006652-sec-0006">Main results</h3> <p>Of 6947 identified citations, 19 RCTs fulfilled the eligibility criteria. These trials enrolled 9650 participants. Trial registries' searches identified nine registered but unpublished trials, two of which were labeled as 'ongoing trials'. In all included RCTs, the intervention consisted of heparin (either unfractionated heparin or low molecular weight heparin). Overall, heparin appears to have no effect on mortality at 12 months (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.93 to 1.03; risk difference (RD) 10 fewer per 1000; 95% CI 35 fewer to 15 more; moderate certainty of evidence) and mortality at 24 months (RR 0.99; 95% CI 0.96 to 1.01; RD 8 fewer per 1000; 95% CI 31 fewer to 8 more; moderate certainty of evidence). Heparin therapy reduces the risk of symptomatic VTE (RR 0.56; 95% CI 0.47 to 0.68; RD 30 fewer per 1000; 95% CI 36 fewer to 22 fewer; high certainty of evidence), while it increases in the risks of major bleeding (RR 1.30; 95% 0.94 to 1.79; RD 4 more per 1000; 95% CI 1 fewer to 11 more; moderate certainty of evidence) and minor bleeding (RR 1.70; 95% 1.13 to 2.55; RD 17 more per 1000; 95% CI 3 more to 37 more; high certainty of evidence). Results failed to confirm or to exclude a beneficial or detrimental effect of heparin on thrombocytopenia (RR 0.69; 95% CI 0.37 to 1.27; RD 33 fewer per 1000; 95% CI 66 fewer to 28 more; moderate certainty of evidence); quality of life (moderate certainty of evidence). </p> </section> <section id="CD006652-sec-0007"> <h3 class="title" id="CD006652-sec-0007">Authors' conclusions</h3> <p>Heparin appears to have no effect on mortality at 12 months and 24 months. It reduces symptomatic VTE and likely increases major and minor bleeding. Future research should further investigate the survival benefit of different types of anticoagulants in patients with different types and stages of cancer. The decision for a patient with cancer to start heparin therapy should balance the benefits and downsides, and should integrate the patient's values and preferences. </p> <p>Editorial note:This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006652-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006652-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006652-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006652-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006652-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006652-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006652-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006652-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006652-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006652-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006652-abs-0002" lang="en"> <h3>Injectable blood thinners (anticoagulants) in patients with cancer</h3> <p><b>Background</b><br/>Research evidence suggests that blood thinners may improve the survival of patients with cancer, by preventing life‐threatening blood clots and might also have a direct anticancer effect. However, blood thinners can also increase the risk of bleeding, which can be serious and reduce survival. It is therefore important to understand the pros and cons of treatment to allow patients and their doctors to be aware of the balance of risks and benefits. </p> <p><b>Study characteristics</b><br/>We searched the scientific literature for studies of anticoagulants in people with cancer. The evidence is current to 14 August 2017. We included 19 eligible trials. </p> <p><b>Key results</b><br/>We selected 19 trials including 9650 participants with cancer. Most trials included participants with various types of cancer, especially small cell lung cancer, non‐small cell lung cancer, and pancreatic cancer. All studies were conducted in the outpatient setting. The results suggest that the effect of injectable blood thinners on survival is uncertain, but if anything of small size. Also the results suggest that injectable blood thinners reduce the risk of blood clots by about half and possibly increase the risk of major bleeding and minor bleeding by 4 more per 1000 and 17 more per 1000, respectively. The effect on quality of life is uncertain. </p> <p><b>Certainty of evidence</b><br/>We judged the certainty of evidence to be high for symptomatic VTE and minor bleeding, and moderate for mortality, major bleeding and quality of life. </p> <p>Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006652-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006652-sec-0073"></div> <h3 class="title" id="CD006652-sec-0074">Implications for practice</h3> <section id="CD006652-sec-0074"> <p>This systematic review found no survival benefit from heparin therapy in patients with cancer patients. Heparin did decrease the number of thrombotic events with likely increases in major bleeding and minor bleeding. </p> <p>The decision for a patient with cancer to start heparin therapy in the absence of a standard therapeutic or prophylactic indication should balance the benefits and downsides, and should integrate the patient's values and preferences (<a href="./references#CD006652-bbs2-0157" title="HaynesRB , DevereauxPJ , GuyattGH . Clinical expertise in the era of evidence-based medicine and patient choice. Vox Sanguinis2002;83(Suppl 1):383-6.">Haynes 2002</a>). Patients with a high preference for a reduction in VTE and limited aversion to potential bleeding, and who do not consider heparin (both unfractionated heparin or low molecular weight heparin (LMWH)) therapy a burden, may opt to use heparin, while those with aversion to bleeding may not. Decisions at a health system level would have to consider the cost‐effectiveness of such as practice. </p> </section> <h3 class="title" id="CD006652-sec-0075">Implications for research</h3> <section id="CD006652-sec-0075"> <p>There is a need to understand the effects of heparin (including unfractionated heparin and LMWH) and other anticoagulants in patients with different types and subtypes (small cell lung cancer versus others) and stages (advanced versus not advanced) of cancers, as well as with existing comorbidites. Similarly, there is a need to understand the differential effects of different types, dosing, schedules and duration of therapy (<a href="./references#CD006652-bbs2-0135" title="AlifanoM , BenedettiG , TrisoliniR . Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer?: An urgent call for research. Chest2004;126:601-7.">Alifano 2004</a>). Some of the ongoing, or as yet unpublished studies may provide such information (<a href="./references#CD006652-bbs2-0122" title="KakkarAK , DovalDC , FareedJ , KerrD , MaganjiJM , MuellerI . Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer. Annals of Oncology2010;21:252-3. ">Kakkar 2010 (GASTRANOX)</a>; <a href="./references#CD006652-bbs2-0124" title="Long-term Prophylaxis of Venous Thromboembolism with low-molecular-weight heparin in patients with metastatic lung cancer. Ongoing study. April 2017. Contact author for more information.">Meyer 2017 (PROVE)</a>. Also, our forthcoming individual patient data (IPD) meta‐analysis will be useful in clarifying how the type and stage of cancer modify the effect of parenteral anticoagulation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006652-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006652-sec-0008"></div> <div class="table" id="CD006652-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin prophylaxis compared with no prophylaxis in ambulatory patients with cancer without VTE receiving systemic therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Heparin prophylaxis compared with no prophylaxis in ambulatory patients with cancer without VTE receiving systemic therapy</b> </p> <p><b>P</b>: Ambulatory patients with cancer without VTE receiving systemic therapy </p> <p><b>I</b>: Heparin prophylaxis </p> <p><b>C</b>: No prophylaxis </p> <p><b>S</b>: Outpatient </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow‐up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with No prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Heparin prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9575<br/>(18 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.93 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 fewer per 1000<br/>(35 fewer to 15 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5229<br/>(14 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.96 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>778 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(31 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9036<br/>(16 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/>(0.47 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 fewer per 1000<br/>(36 fewer to 22 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9592<br/>(18 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/>(0.94 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(1 fewer to 11 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9245<br/>(16 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70<br/>(1.13 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 more per 1000<br/>(3 more to 37 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5832<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/>(0.37 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/>(66 fewer to 28 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life impairment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2241<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Macbeth 2016 (FRAGMATIC): " There was no difference between the two groups with respect to quality‐adjusted life years gained in the first year... No difference in overall quality of life at 6 months (P = .94) or at 12 months (P = .89)... Overall quality of life did not change significantly over the study period".Sideras 2006: "The QOL and SDS scores were similar, both at baseline and during the protocol period, in patients randomized to receive LMWH vs those not randomized to receive LMWH." </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision: Confidence interval includes values suggesting clinically significant benefit and values suggesting no effect. </p> <p><sup>2</sup> Downgraded one level due to serious imprecision: Confidence interval includes values suggesting clinically significant harm and values suggesting no effect. </p> <p><sup>3</sup> Downgraded one level due to serious imprecision: Confidence interval includes values suggesting clinically significant benefit and values suggesting harm. </p> <p><sup>4</sup> Downgraded one level due to serious risk of bias: Both studies were open‐label studies (lack of blinding may impact the patient‐reported subjective outcomes) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006652-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006652-sec-0009"></div> <p>Please refer to the glossary for the definitions of technical terms (<a href="#CD006652-tbl-0002">Table 1</a>). </p> <div class="table" id="CD006652-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assisting in the amelioration or cure of disease</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The process of hindering the clotting of blood especially by treatment with an anticoagulant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antithrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used against or tending to prevent thrombosis (clotting)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacteremia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The presence of bacteria in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central venous line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Synthetic tube that is inserted into a central (large) vein of a patient to provide temporary intravenous access for the administration of fluid, medication or nutrients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (such as swelling and pain) and that is potentially life‐threatening if dislodgment of the thrombus results in pulmonary embolism </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fibrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A white insoluble fibrous protein formed from fibrinogen by the action of thrombin, especially in the clotting of blood </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fondaparinux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anticoagulant medication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hemostatic system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The system that shortens the clotting time of blood and stops bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. Two forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impedance plethysmography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kappa statistics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A measure of degree of non‐random agreement between observers and/or measurements of a specific categorical variable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The spread of cancer cells from the initial or primary site of disease to another part of the body </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oncogene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A gene having the potential to cause a normal cell to become cancerous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Osteoporosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A condition that especially affects older women and is characterized by a decrease in bone mass with decreased density and enlargement of bone spaces producing porosity and brittleness </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parenteral nutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The practice of feeding a patient intravenously, circumventing the gut</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing, chest pain, fainting, rapid heart rate, cyanosis, shock and sometimes death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The supporting framework of an organ typically consisting of connective tissue</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A proteolytic enzyme formed from prothrombin that facilitates the clotting of blood by catalyzing conversion of fibrinogen to fibrin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistent decrease in the number of blood platelets that is often associated with hemorrhagic conditions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The formation or presence of a blood clot within a blood vessel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin K antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anticoagulant medication that is a vitamin K antagonist, which is used for anticoagulation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anticoagulant medication</p> </td> </tr> </tbody> </table> </div> <section id="CD006652-sec-0010"> <h3 class="title" id="CD006652-sec-0010">Description of the condition</h3> <p>Since the 1930s, scientists have been exploring the effects of anticoagulation on cancer (<a href="./references#CD006652-bbs2-0172" title="SmorenburgSM , Van NoordenCJ . The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacological Reviews2001;53(1):93-105.">Smorenburg 2001</a>). Studies have implicated the tumor‐mediated activation of the hemostatic system in both the formation of tumor stroma and in tumor metastasis (<a href="./references#CD006652-bbs2-0150" title="DvorakHF . Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine1986;315(26):1650-9.">Dvorak 1986</a>; <a href="./references#CD006652-bbs2-0153" title="FrancisJL , BiggerstaffJ , AmirkhosraviA . Hemostasis and malignancy. Seminars in Thrombosis and Hemostasis1998;24(2):93-109.">Francis 1998</a>; <a href="./references#CD006652-bbs2-0162" title="LevineMN , LeeAY , KakkarAK . From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. Journal of Thrombosis and Haemostasis2003;1(7):1456-63.">Levine 2003</a>). There is also evidence that heparin inhibits expression of oncogenes and formation of thrombin and fibrin induced by cancer cells (<a href="./references#CD006652-bbs2-0172" title="SmorenburgSM , Van NoordenCJ . The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacological Reviews2001;53(1):93-105.">Smorenburg 2001</a>). In addition, heparin potentially inhibits intravascular arrest of cancer cells and thus metastasis (<a href="./references#CD006652-bbs2-0172" title="SmorenburgSM , Van NoordenCJ . The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacological Reviews2001;53(1):93-105.">Smorenburg 2001</a>). </p> </section> <section id="CD006652-sec-0011"> <h3 class="title" id="CD006652-sec-0011">Description of the intervention</h3> <p>Heparin and low molecular weight heparins (LMWHs), fondaparinux and danaparoid do not have intrinsic anticoagulant activity but potentiate the activity of antithrombin III in inhibiting activated coagulation factors. These agents constitute indirect anticoagulants as their activity is mediated by plasma cofactors. Recombinant hirudin, bivalirudin and argatroban directly inhibit thrombin and are classified as direct anticoagulants (<a href="./references#CD006652-bbs2-0160" title="HirshJ , BauerKA , DonatiMB , GouldM , SamamaMM , WeitzJI . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008;133(Suppl):141s-59s.">Hirsh 2008</a>). Heparin and its low molecular weight derivatives are not absorbed orally and must be administered parenterally by intravenous infusion or subcutaneous injections (<a href="./references#CD006652-bbs2-0159" title="HirshJ . Low molecular weight heparin. Thrombosis and Haemostasis1993;70(1):204-7.">Hirsh 1993</a>). </p> </section> <section id="CD006652-sec-0012"> <h3 class="title" id="CD006652-sec-0012">How the intervention might work</h3> <p>Researchers have hypothesized that heparin may improve outcomes in patients with cancer through an anti‐tumor effect in addition to its antithrombotic effect (<a href="./references#CD006652-bbs2-0175" title="ThodiyilP , KakkarAK . Can low-molecular-weight heparins improve outcomes in patients with cancer?Cancer Treatment Reviews2002;28:151-5.">Thodiyil 2002</a>). In a 1992 clinical trial comparing nadroparin, a LMWH, with unfractionated heparin in patients with proven deep vein thrombosis (DVT), nadroparin unexpectedly reduced mortality in the subgroup of patients with cancer (<a href="./references#CD006652-bbs2-0167" title="PrandoniP , LensingAW , BullerHR , CartaM , CogoA . Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339:441-5.">Prandoni 1992</a>). At the same time, anticoagulants increase the risk for bleeding. In fact, in patients with venous thrombosis on anticoagulation, the risk of bleeding was higher if patients had cancer and correlated with the extent of cancer (<a href="./references#CD006652-bbs2-0168" title="BernardiE , SimioniP , GirolamiB , MarchioriA , SabbionP , PrinsM , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100(10):3484-8.">Prandoni 2002</a>). Heparins are also known to cause thrombocytopenia (reduced numbers of platelets) and heparin‐induced thrombocytopenia (HIT) syndrome (<a href="./references#CD006652-bbs2-0154" title="GirolamiB , GirolamiA . Heparin-induced thrombocytopenia: a review. Seminars in Thrombosis and Hemostasis2006;32(8):803-9.">Girolami 2006</a>). </p> </section> <section id="CD006652-sec-0013"> <h3 class="title" id="CD006652-sec-0013">Why it is important to do this review</h3> <p>We initially conducted this and other reviews on this topic and their updates to directly and better inform clinical practice guidelines. The last update of this systematic review, published in 2014 (<a href="./references#CD006652-bbs2-0182" title="AklEA , KahaleLA , BalloutRA , BarbaM , YosuicoVE , vanDoormaalFF , et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 12. Art. No: CD006652. [DOI: 10.1002/14651858.CD006652.pub4]">Akl 2014 (parenteral)</a>), identified 15 trials enrolling 7662 participants (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0165" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. ">Pelzer 2009 (CONKO‐2004)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>). The included trials provided high‐certainty evidence for a reduction of venous thromboembolism (VTE) with heparin thromboprophylaxis compared to no heparin thromboprophylaxis. Since then, we have identified three eligible trials addressing this question (<a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>) and the full‐text publication of a previously included abstract (<a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>. </p> <p><b>Living systematic review approach:</b> Following the publication of this current 2017 update of the review, we will maintain it as a living systematic review. This means we will be continually running the searches and rapidly incorporating any newly identified evidence (for more information about the living systematic review approach being piloted by Cochrane, see <a href="./appendices#CD006652-sec-0079">Appendix 1</a>. We believe a living systematic review approach is appropriate for this review for four reasons. First, the review addresses an important topic for clinical practice; patients with cancer have a relatively high rate of VTE, up to 17.7% (<a href="./references#CD006652-bbs2-0137" title="AyC , DunklerD , MarosiC , ChiriacAL , VormittagR , SimanekR , et al. Prediction of venous thromboembolism in cancer patients. Blood2010;116(24):5377-82.">Ay 2010</a>). In addition, the occurrence of VTE is associated with a 2.3 increased risk of death in patients with breast and non‐small cell lung cancer (NSCLC), 2.5 times lengthening of hospital stay among patients with lung cancer, and 50% higher total cost for patients with lung cancer (<a href="./references#CD006652-bbs2-0142" title="ChewHK , DaviesAM , WunT , HarveyD , ZhouH , WhiteRH . The incidence of venous thromboembolism among patients with primary lung cancer. Journal of Thrombosis Haemostasis2008;6:601–8.">Chew 2008</a>, <a href="./references#CD006652-bbs2-0141" title="ChewHK , WunT , HarveyDJ , ZhouH , WhiteRH . Incidence of venous thromboembolism and the impact on survival in breast cancer patients. Journal of Clinical Oncology2007;25:70–6.">Chew 2007</a>; <a href="./references#CD006652-bbs2-0145" title="ConnollyGC , DalalM , LinJ , KhoranaAA . Incidence and predictors ofvenous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer2012;78:253–8.">Connolly 2012</a>). Second, there remains uncertainty in the existing evidence base; the 2014 update of this systematic review found a potential subgroup effect on all‐cause mortality at one year, with a possible higher reduction in mortality among patients with small cell lung cancer (SCLC) compared to other types of cancer. Third, we are aware of several recently published and ongoing trials in this area that will be important to incorporate in a timely manner. Fourth, we are planning to use this living systematic review as the basis of a living recommendation in a clinical practice guideline with the American Society of Hematology (<a href="./references#CD006652-bbs2-0134" title="AklEA , MeerpohlJJ , ElliottJH , KahaleLA , Schünemann HJ on behalf of the Living Systematic Review Network. Living systematic reviews: 4. living guideline recommendations. Journal of Clinical Epidemiology (in press)2017.">Akl 2017</a>). For more information about the living systematic review approach being piloted by Cochane, see <a href="./appendices#CD006652-sec-0080">Appendix 2</a>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006652-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006652-sec-0014"></div> <p>To evaluate the effectiveness and safety of parenteral anticoagulants in ambulatory patients with cancer. Typically, these patients are undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006652-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006652-sec-0015"></div> <section id="CD006652-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006652-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs).</p> </section> <section id="CD006652-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants with cancer with no standard indication for prophylactic anticoagulation (e.g. for acute illness, for central venous line placement, perioperatively) or for therapeutic anticoagulation (e.g. for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)). Patients could have been of any age group (including children). Typically, these participants are undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy. </p> </section> <section id="CD006652-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Intervention arm: parenteral anticoagulants, such as unfractionated heparin or low molecular weight heparin (LMWH). </p> <p>Comparator intervention: placebo or no intervention.</p> <p>The trial protocol should have planned to provide all other co‐interventions (e.g. chemotherapy) similarly. </p> </section> <section id="CD006652-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD006652-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006652-list-0001"> <li> <p>All‐cause mortality; pre‐specified at 12 months, 24 months and over the duration of the trial. </p> </li> </ul> </p> </section> <section id="CD006652-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006652-list-0002"> <li> <p>Symptomatic DVT: DVT events had to be suspected clinically, and diagnosed using an objective diagnostic test such as: venography, 125I‐fibrinogen‐uptake test, impedance plethysmography or compression ultrasound. </p> </li> <li> <p>PE: PE events had to be suspected clinically, and diagnosed using an objective diagnostic test such as: pulmonary perfusion/ventilation scans, computed tomography, pulmonary angiography or autopsy. </p> </li> <li> <p>Major bleeding: we accepted the authors' definitions of major bleeding.</p> </li> <li> <p>Minor bleeding: we accepted the authors' definitions of minor bleeding.</p> </li> <li> <p>Health‐related quality of life: had to be measured using a validated tool.</p> </li> <li> <p>Thrombocytopenia.</p> </li> </ul> </p> </section> </section> </section> <section id="CD006652-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006652-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The search was part of a comprehensive search for studies of anticoagulation in patients with cancer. We did not use language restrictions. We conducted comprehensive searches on 14 August 2017, following the original electronic searches in January 2007, February 2010, February 2013, and February 2016 (last major search). We electronically searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (starting 1946), and Embase (starting 1980; accessed via OVID) . The search strategies combined terms for anticoagulants, terms for cancer and a search filter for RCTs. We list the full search strategies for each of the electronic databases in <a href="./appendices#CD006652-sec-0081">Appendix 3</a>, <a href="./appendices#CD006652-sec-0082">Appendix 4</a>, and <a href="./appendices#CD006652-sec-0083">Appendix 5</a>, respectively. </p> <p><b>Living systematic review approach:</b> Since the last major search in February 2016, we have been running searches monthly, using auto‐alerts to deliver the monthly yield by email. We will incorporate new evidence rapidly after it is identified. This update of the systematic review is based on the findings of a literature search conducted on 14 August 2017. We will review search methods and strategies approximately yearly, to ensure they reflect any terminology changes in the topic area, or in the databases. </p> </section> <section id="CD006652-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched the conference proceedings of the American Society of Clinical Oncology (ASCO, starting with its first volume, 1982 up to August 2017) and of the American Society of Hematology (ASH, starting with its 2003 issue up to August 2017).We also searched <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://www.who.int/ictrp/search/en/" target="_blank">WHO International Clinical Trials Registry Platform</a> for ongoing studies. We reviewed the reference lists of papers included in this review and of other relevant systematic reviews. We used the 'related citation' feature in PubMed to identify additional articles and 'citation tracking' of included studies in Web of Science Core Collection.In addition, experts in the field were contacted for information about unpublished and ongoing trials. </p> <p><b>Living systematic review approach:</b> We will search the conference proceedings of ASCO and ASH soon after their publications, <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, and <a href="http://www.who.int/ictrp/search/en/" target="_blank">WHO International Clinical Trials Registry Platform</a> on a monthly basis. As an additional step, we will contact corresponding authors of ongoing studies as they are identified and ask them to advise when results are available. We will continue to review the reference lists for any prospectively identified studies, with running the 'related citation' for all included studies on a monthly basis. Also, we will contact the corresponding authors of any newly included studies for advice as to other relevant studies. We will conduct citation tracking of included studies in Web of Science Core Collection on an ongoing basis, using citation alerts in Web of Science Core Collection. </p> </section> </section> <section id="CD006652-sec-0026"> <h3 class="title" id="CD006652-sec-0026">Data collection and analysis</h3> <section id="CD006652-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts of identified articles for eligibility. We retrieved the full text of articles judged as potentially eligible by at least one review author. Two review authors then independently screened the full‐text articles for eligibility using a standardized form with explicit inclusion and exclusion criteria. The two review authors resolved their disagreements by discussion or by consulting a third review author. </p> <p><b>Living systematic review approach:</b> For the monthly searches, we will immediately screen any new citations retrieved each month. As the first step of monthly screening, we will apply the machine learning classifier (RCT model) available in the Cochrane Register of Studies (<a href="./references#CD006652-bbs2-0146" title="CSR-web. http://community.cochrane.org/tools/data-management-tools/crs. ..">CSR‐Web</a>; <a href="./references#CD006652-bbs2-0176" title="WallaceBC , Noel-StorrA , MarshallIJ , CohenAM , SmalheiserNR , ThomasJ . Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach. Journal of the American Medical Informatics Association2017;0(0):1-4. [DOI: 10.1093/jamia/ocx053]">Wallace 2017</a>). The classifier assigns a probability (from 0 to 100) to each citation for being a true RCT. For citations that are assigned a probability score of less than 10, the machine learning classifier currently has a specificity/recall of 99.987% (James Thomas, personal communication). For citations assigned a score from 10 to 100, we will screen them in duplicate and independently. Citations that score 9 or less will be screened by Cochrane Crowd (<a href="./references#CD006652-bbs2-0143" title="Cochrane Crowd. http://crowd.cochrane.org. ..">Cochrane Crowd</a>). Any citations that are deemed to be potential RCTs by Cochrane Crowd will be returned to the authors for screening. </p> </section> <section id="CD006652-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from each included study and resolved their disagreements by discussion. We aimed to collect data related to the following. </p> <section id="CD006652-sec-0029"> <h5 class="title">Participants</h5> <p> <ul id="CD006652-list-0003"> <li> <p>Number of participants randomized to each treatment arm.</p> </li> <li> <p>Number of participants followed up in each treatment arm.</p> </li> <li> <p>Number of withdrawals from treatment in each treatment arm.</p> </li> <li> <p>Population characteristics (age, gender, co‐morbidity).</p> </li> <li> <p>History of VTE.</p> </li> <li> <p>Type of cancer (site and histology).</p> </li> <li> <p>Stage of cancer.</p> </li> <li> <p>Time since cancer diagnosis.</p> </li> </ul> </p> </section> <section id="CD006652-sec-0030"> <h5 class="title">Interventions</h5> <p> <ul id="CD006652-list-0004"> <li> <p>Type of anticoagulant: unfractionated heparin, LMWH or fondaparinux.</p> </li> <li> <p>Dose: prophylactic versus therapeutic (<a href="#CD006652-tbl-0003">Table 2</a>). </p> </li> <li> <p>Duration of treatment.</p> </li> <li> <p>Control: placebo or no intervention.</p> </li> <li> <p>Co‐interventions including chemotherapy and hormonal therapy, immunotherapy and radiotherapy (type and duration). </p> </li> </ul> </p> <div class="table" id="CD006652-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">LMWH: definitions of prophylactic and therapeutic dosages</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LMWH</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Generic name</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic dose</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic dose</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lovenox</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enoxaparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/kg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fragmin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dalteparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2500 to 5000 units once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 U/kg once daily or<br/>100 U/kg twice daily </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Innohep, Logiparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinzaparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4500 units once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 U/kg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fraxiparine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nadroparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 to 75 anti‐Xa international units/kg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 anti‐Xa int. units/kg once daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certoparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sandoparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3000 anti‐Xa international units once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006652-sec-0031"> <h5 class="title">Outcomes</h5> <p>We extracted both time‐to‐event data (for the survival outcome) and dichotomous data (for all outcomes). For mortality, we collected data for the pre‐specified time point of 12 months, but also for 24 months and for over the duration of follow‐up. </p> <p>For time‐to‐event survival data, we abstracted the log(hazard ratio (HR)) and its variance from trial reports. If these were not reported, we digitized the published Kaplan‐Meier survival curves and estimated the log(HR) and its variance using Parmar's methods (<a href="./references#CD006652-bbs2-0164" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>). We also noted the minimum and maximum duration of follow‐up, which are required to make these estimates. We performed these calculations in Stata 9, using a specially written program, which yielded the reported log(HR) and variance when used on the data presented in Table V of <a href="./references#CD006652-bbs2-0164" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>. </p> <p>For dichotomous data, we extracted data necessary to conduct complete case analysis as the primary analysis. We collected all‐cause mortality at one year (time point defined a priori in the protocol) and at two years (time point defined post hoc based upon results reported in the individual RCTs). When we could not obtain the number of events at the time points of interest from the paper or from the authors, two review authors calculated these numbers independently and in duplicate from survival curves, if available (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>). We used the mean of the two estimates when they differed. We assessed agreement between the two authors for each estimated value by calculating the percentage difference, which is the difference between the two estimates divided by the denominator (number of people at risk for the event) and multiplied by 100. For some studies, where VTE is not reported as a separate outcome, we added the number of events of DVT and PE. </p> <p>We attempted to contact study authors for incompletely reported data. We decided a priori to consider abstracts in the main analysis only if authors supplied us with full reports of their methods and results. </p> </section> <section id="CD006652-sec-0032"> <h5 class="title">Other</h5> <p>We extracted from each included trial any information on the following points:</p> <p> <ul id="CD006652-list-0005"> <li> <p>source of funding;</p> </li> <li> <p>ethical approval;</p> </li> <li> <p>conflict of interest.</p> </li> </ul> </p> </section> </section> <section id="CD006652-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias at the study level using the Cochrane 'Risk of bias' tool (<a href="./references#CD006652-bbs2-0144" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Available from www.cochrane-handbook.org2009.">Cochrane Handbook</a>). Two review authors independently assessed the risk of bias of each included study and resolved their disagreements by discussion. 'Risk of bias' criteria included: </p> <p> <ul id="CD006652-list-0006"> <li> <p>adequate sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>percentage of follow‐up and whether incomplete outcome data were addressed;</p> </li> <li> <p>whether the study was free of selective reporting; and</p> </li> <li> <p>whether the study was stopped early for benefit.</p> </li> </ul> </p> <p>See section on <a href="#CD006652-sec-0036">Dealing with missing data</a> about assessing risk of bias associated with participants with missing data. </p> </section> <section id="CD006652-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We collected and analyzed hazard ratios (HRs) for time‐to‐event data and risk ratios (RRs) for dichotomous data. None of the outcomes of interest was meta‐analyzed as a continuous variable. </p> </section> <section id="CD006652-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant.</p> </section> <section id="CD006652-sec-0036"> <h4 class="title">Dealing with missing data</h4> <section id="CD006652-sec-0037"> <h5 class="title">Determining participants with missing data</h5> <p>It was not clear whether certain participant categories (e.g. those described as "withdrew consent" or "experienced adverse events") were actually followed up by the trial authors (versus had missing participant data) (<a href="./references#CD006652-bbs2-0133" title="AklEA , KahaleLA , EbrahimS , Alonso-CoelloP , SchünemannHJ , GuyattGH . Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers.. Journal of Clinical Epidemiology2016;76:147-54.">Akl 2016</a>). To deal with this issue, we made the following considerations: </p> <p> <ul id="CD006652-list-0007"> <li> <p>"ineligible participants" and "did not receive the first dose" participant categories, which are defined prior to the initiation of the study intervention, most likely have missing participant data; </p> </li> <li> <p>"withdrew consent", "lost to follow‐up" and "outcome not assessable" participant categories and other category explicitly reported as not being followed‐up, which are defined after the initiation of the study intervention, most likely have missing participant data; </p> </li> <li> <p>"dead", "experienced adverse events", "non‐compliant", "discontinued prematurely" and similarly described participant categories are less likely to have missing participant data. </p> </li> </ul> </p> </section> <section id="CD006652-sec-0038"> <h5 class="title">Dealing with participants with missing data in the primary meta‐analysis</h5> <p>In the primary meta‐analysis, we used a complete case analysis approach, i.e. we excluded participants considered to have missing data (<a href="./references#CD006652-bbs2-0156" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017:pii: S0895-4356(16)30811-3.">Guyatt 2017</a>). </p> <p>For categorical data, we used the following calculations for each study arm.</p> <p> <ul id="CD006652-list-0008"> <li> <p>Denominator: (number of participants randomized) ‐ (number of participants most likely with missing data, both pre‐ and post‐intervention initiation). </p> </li> <li> <p>Numerator: number of participants with observed events (i.e. participants who suffered at least one event for the outcome of interest during their available follow‐up time). </p> </li> </ul> </p> <p>For continuous data, we planned to use for each study arm the reported mean and standard deviation for participants actually followed up by the trial authors. </p> </section> <section id="CD006652-sec-0039"> <h5 class="title">Assessing the risk of bias associated with participants with missing data</h5> <p>When the primary meta‐analysis of a specific outcome found a statistically significant effect, we conducted sensitivity meta‐analyses to assess the risk of bias associated with missing participant data. Those sensitivity meta‐analyses used a priori plausible assumptions about the outcomes of participants considered to have missing data. The assumptions we used in the sensitivity meta‐analyses were increasingly stringent in order to progressively challenge the statistical significance of the results of the primary analysis (<a href="./references#CD006652-bbs2-0128" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLOS One2013;8(2):e57132.">Akl 2013</a>; <a href="./references#CD006652-bbs2-0151" title="EbrahimS , AklEA , MustafaRA , SunX , WalterSD , Heels-AnsdellD , et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology2013;66(9):1014-21.">Ebrahim 2013</a>). </p> <p>For categorical data, and for RR showing a reduction in effect (RR &lt; 1), we used the following increasingly stringent but plausible assumptions (<a href="./references#CD006652-bbs2-0128" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLOS One2013;8(2):e57132.">Akl 2013</a>): </p> <p> <ul id="CD006652-list-0009"> <li> <p>for the control arm, relative incidence (RI) among those with missing data (lost to follow‐up (LTFU)) compared to those with available data (followed up, FU) in the same arm (RI<sub>LTFU/FU</sub>) = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 1.5; </p> </li> <li> <p>for the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 2; </p> </li> <li> <p>for the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 3; </p> </li> <li> <p>for the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 5. </p> </li> </ul> </p> <p>For RR showing an increase in effect (RR &gt; 1), we switched the above assumptions between the control and interventions arms (i.e. used RI<sub>LTFU/FU</sub> = 1 for the intervention arm). </p> <p>Specifically, we used the following calculations for each study arm.</p> <p> <ul id="CD006652-list-0010"> <li> <p>Denominator: (number of participants randomized) ‐ (number of participants most likely with missing data, pre‐intervention initiation). </p> </li> <li> <p>Numerator: (number of participants with observed events) + (number of participants most likely with missing data post‐intervention initiation, with assumed events). </p> </li> </ul> </p> <p>Assumed events are calculated by applying the a priori plausible assumptions to the participants considered most likely with missing data post‐intervention initiation. </p> <p>For continuous data, we planned to use the four strategies suggested by Ebrahim and colleagues. The strategies imputed the means for participants with missing data based on the means of participants actually followed up in individual trials included in the systematic review. To impute standard deviation (SD), we used the median SD from the control arms of all included trials (<a href="./references#CD006652-bbs2-0151" title="EbrahimS , AklEA , MustafaRA , SunX , WalterSD , Heels-AnsdellD , et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology2013;66(9):1014-21.">Ebrahim 2013</a>). </p> </section> </section> <section id="CD006652-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials which cannot be ascribed to sampling variation (<a href="./references#CD006652-bbs2-0158" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD006652-bbs2-0147" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London: BMJ Publication Group, 2001.">Deeks 2001</a>). If there was evidence of substantial heterogeneity, we attempted to investigate the possible reasons for this (see section on <a href="#CD006652-sec-0043">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD006652-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed for selective outcome reporting by trying to identify whether the study was included in a trial registry, whether a protocol was available, and whether the methods section provided a list of outcomes. We compared the list of outcomes from those sources to the outcomes reported in the published paper. We also assessed for possible publication bias by creating an inverted funnel plot for the primary outcome of survival. </p> </section> <section id="CD006652-sec-0042"> <h4 class="title">Data synthesis</h4> <p>For time‐to‐event data, we pooled the log(HRs) using a random‐effects model (<a href="./references#CD006652-bbs2-0148" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>), and the generic inverse variance facility of <a href="./references#CD006652-bbs2-0169" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>. For dichotomous data, we calculated the RR separately for each study. When analyzing data related to participants who were reported as not compliant, we attempted to adhere to the principles of intention‐to‐treat (ITT) analysis. We approached the issue of non‐compliance independently from that of missing data (<a href="./references#CD006652-bbs2-0136" title="AlshurafaM , BrielM , AklEA , HainesT , MoayyediP , GentlesSJ , et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLOS One2012;7(11):e49163.">Alshurafa 2012</a>). We then pooled the results of the different studies using a random‐effects model. We assessed the certainty of evidence at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD006652-bbs2-0155" title="SchünemannH , BrożekJ , GuyattG , OxmanA . GRADE Handbook. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html Updated October 2013.">GRADE handbook</a>). </p> <p><b>Living systematic review approach:</b> Whenever new evidence (studies, data or information) that meets the review inclusion criteria is identified, we will immediately assess risk of bias and extract the data and incorporate it in the synthesis, as appropriate. We will not adjust the meta‐analyses to account for multiple testing given the methods related to frequent updating of meta‐analyses are under development (<a href="./references#CD006652-bbs2-0171" title="SimmondsME , SalantiG , HigginsJE , McKenzieJ , Elliott JE on behalf of the Living Systematic Review Network. Living Systematic Reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology (in press)2017.">Simmonds 2017</a>). </p> </section> <section id="CD006652-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to explore heterogeneity by conducting subgroup analyses based on the characteristics of participants (type and stage of cancer, and whether participants were on cancer treatment or not). In particular, we conducted subgroup analyses for patients with (1) lung cancer (either SCLC or NSCLC) versus those with non‐lung cancer; (2) patients with advanced cancer versus those with non‐advanced cancer. We included in the lung versus non lung subgroup analysis data from: </p> <p> <ul id="CD006652-list-0011"> <li> <p>studies that recruited only patients with lung cancer (either SCLC or NSCLC) and studies that recruited only patients with non‐lung cancer; </p> </li> <li> <p>studies that recruited both lung and non‐lung cancer if they provided data for subgroups of patients with lung cancer AND data for subgroups of patients with non‐lung cancer; </p> </li> <li> <p>studies that recruited both lung and non‐lung cancer but did not provide subgroup data, if more than 75% of participants had lung cancer or more than 75% of participants had non‐lung cancer. </p> </li> </ul> </p> <p>Similarly for the subgroup analysis for non‐advanced cancer. We planned to assess the credibility of subgroup effect, when statistically significant, using the criteria suggested by <a href="./references#CD006652-bbs2-0173" title="SunX , BrielM , WalterSD , GuyattGH . Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010 Mar 30;340:c117.">Sun 2010</a>. </p> </section> <section id="CD006652-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned for sensitivity analyses excluding trials at high risk of bias. As described above, we also planned for sensitivity meta‐analyses to assess the risk of bias associated with missing participant data when the primary meta‐analysis of a specific outcome found a statistically significant effect. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006652-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006652-sec-0045"></div> <section id="CD006652-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD006652-sec-0047"> <h4 class="title">Results of the search</h4> <p><a href="#CD006652-fig-0001">Figure 1</a> shows the study flow diagram. As of August 2017, the search strategy identified a total of 6947 unique citations. The title and abstract screening identified 192 potentially eligible citations. The full‐text screening of the full texts of these 192 citations identified 18 eligible RCTs published as full reports (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>; <a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>), and one RCT published as abstract (<a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a>) We had also identified two eligible studies published as abstracts but for which we were not able to obtain the necessary data from the authors: <a href="./references#CD006652-bbs2-0170" title="SalatC , BreitruckH , ReinhardtB , HillerE . Thromboprophylaxis with low molecular weight heparin (LMWH) and conventional low dose heparin in patients with malignant diseases. Blut1990;61(2-3):142.">Salat 1990</a>, <a href="./references#CD006652-bbs2-0139" title="ChazouilleresO , PouponR , GatineausaillantG , RoulotD , BarbareJC , LabadieH , et al. Beneficial effect of low molecular weight heparin (fraxiparin) on short term mortality in patients with unresectable hepatocellular carcinoma (HCC). A randomized study. Gastroenterology1994;106(4):A874.">Chazouilleres 1994</a>,. We identified nine registered but unpublished trials: four completed (<a href="./references#CD006652-bbs2-0119" title="A randomized phase II open-label study to assess the efficacy &amp; safety of gemcitabine + Abraxane® with or without ODSH (2-0, 3-0 desulfated heparin) as first line treatment of metastatic pancreatic cancer. Ongoing study. November 2011. Contact author for more information.">Borad 2011 (PGPC1)</a>; <a href="./references#CD006652-bbs2-0121" title="Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in patients with stage IIIB and IV NSCLC undergoing a cisplatin based first line chemotherapy: the SYRINGES Trial. Ongoing study. June 2008. Contact author for more information.">Germonpre 2008 (SYRINGES)</a>; <a href="./references#CD006652-bbs2-0122" title="KakkarAK , DovalDC , FareedJ , KerrD , MaganjiJM , MuellerI . Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer. Annals of Oncology2010;21:252-3. ">Kakkar 2010 (GASTRANOX)</a>; <a href="./references#CD006652-bbs2-0125" title="Phase III double-blind trial comparing low-molecular weight heparin (LMWH) versus placebo in patients with advanced cancer. Ongoing study. December 1998. Contact author for more information.">Okuno 1999</a>); two terminated (<a href="./references#CD006652-bbs2-0120" title="Chemotherapy with or without preventive anticoagulation for metastatic cancer of the pancreas. Ongoing study. October 2007. Contact author for more information.">Chibauldel 2008 (PAM07)</a>; <a href="./references#CD006652-bbs2-0126" title="A prospective randomized controlled multicenter study of the effect of dalteparin on quality of life in unresectable pancreatic cancer. Ongoing study. October 2002. Contact author for more information.">Pandya 2002</a>); two ongoing (<a href="./references#CD006652-bbs2-0123" title="A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer. Ongoing study. June 2008. Contact author for more information.">Lars 2008 (RASTEN)</a>; <a href="./references#CD006652-bbs2-0124" title="Long-term Prophylaxis of Venous Thromboembolism with low-molecular-weight heparin in patients with metastatic lung cancer. Ongoing study. April 2017. Contact author for more information.">Meyer 2017 (PROVE)</a>); and one withdrawn prior to enrolment (<a href="./references#CD006652-bbs2-0127" title="A randomized phase II study to evaluate the effect of two different doses of enoxaparin sodium in combination with standard chemotherapy (cisplatin plus etoposide) with respect to time to tumor progression (TTP) in patients with newly diagnosed extensive stage small cell lung cancer (SCLC) without underlying venous thromboembolism. Ongoing study. July 2008. Contact author for more information.">Rosovsky 2009</a>). </p> <div class="figure" id="CD006652-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006652-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006652-sec-0048"> <h4 class="title">Included studies</h4> <p>The 19 included studies had 9650 participants. One study used unfractionated heparin as the intervention (<a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>), another used ultra‐LMWH (<a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>), while the other 17 used LMWH as the intervention (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>; <a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>). We did not identify any study using fondaparinux as the intervention. </p> <p>Agnelli and colleagues (PROTECHT trial) recruited 1150 ambulatory participants with metastatic or locally advanced cancer (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>). Participants were randomized to receive a prophylactic dose of nadroparin or placebo, each with concomitant chemotherapy. The primary efficacy outcomes were symptomatic DVT, and PE. The secondary efficacy outcomes were asymptomatic thromboembolic events incidentally diagnosed, and survival at the end of study treatment and at 12 months. Study outcomes included survival, asymptomatic VTE, and minor and major bleeding. Follow‐up was about 90% in each group. </p> <p>Agnelli and colleagues (SAVE‐ONCO trial) recruited 3212 participants with advanced metastatic or locally advanced cancer. Of the participants, 91% had an ECOG performance status of zero or one and 42% had at least one risk factor for VTE (<a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>). Participants were randomized to receive either subcutaneous injection of semuloparin or placebo for a minimum of three months. The study outcomes included mortality, PE, symptomatic DVT, major bleeding and minor bleeding. Follow‐up data were available for 99% of participants for mortality and VTE outcomes. The minimum duration of follow‐up was up to three days after last injection, with a median of 3.5 months. The maximum duration of follow‐up was 12 months. </p> <p>Altinbas and colleagues recruited 84 participants with both limited and extensive SCLC and an Eastern Cooperative Oncology Group (ECOG) status &lt; 3 (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>). The ECOG performance Status scale ranges from zero (fully active) to five (dead) (<a href="./references#CD006652-bbs2-0163" title="OkenMM , CreechRH , TormeyDC , HortonJ , DavisTE , McFaddenET , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology1982;5(6):649-55.">Oken 1982</a>). Participants were randomized to receive either a prophylactic dose of a LMWH (dalteparin) or placebo for 18 weeks or less, in combination with chemotherapy in case of disease progression. Study outcomes included mortality (at 12 and 24 months), symptomatic DVT and bleeding. Follow‐up was complete (100%). The minimum and maximum duration of follow‐up were two and 33 months, respectively. Hazard ratios (HRs) were estimated from published survival curves. </p> <p>Haas and colleagues conducted two multi‐centre double‐blind studies and recruited 900 ambulatory participants receiving chemotherapy for disseminated metastatic breast carcinoma (<a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; n = 353) or stage III/IV NSCLC carcinoma (<a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; n = 547). Participants were randomized to receive either subcutaneous certoparin or placebo for six months. The study outcomes included mortality, confirmed VTE, PE, DVT, thrombocytopenia, major bleeding and minor bleeding. A number of participants were not included in the intention‐to‐treat (ITT) analysis but it is not reported whether they were followed up. The minimum duration of follow‐up was six months. </p> <p>Kakkar and colleagues recruited 385 participants with advanced stage III or IV malignant disease of the breast, lung, gastrointestinal tract, pancreas, liver, genitourinary tract, ovary or uterus, and a minimum life expectancy of three months (<a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>). Participants were randomized to receive either a prophylactic dose of a LMWH (dalteparin) or placebo for 12 months, with no restriction on concomitant chemotherapy or radiotherapy. The study outcomes included mortality (at 12, 24 and 36 months), symptomatic VTE (PE, DVT), major bleeding and minor bleeding. Follow‐up data were available for 374 participants (97%). The minimum duration of follow‐up was not reported. The maximum duration of follow‐up was 81 months. HRs were estimated from published survival curves, assuming all participants were followed up for 77 months. </p> <p>Khorana and colleagues conducted a multi‐center study and recruited 98 participants with cancer and a Khorana risk score of ≥ 3 (<a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>). Participants were randomized to subcutaneous dalteparin or observation for a period of 12 weeks. The study outcomes included symptomatic DVT and PE, and clinically significant major and non‐major bleeding. Follow‐up was complete (100%). The study was terminated early due to low accrual. </p> <p>Klerk and colleagues (MALT trial) recruited 302 participants with different types of advanced solid malignant tumors and a minimum life expectancy of one month (<a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>). Participants were randomized to receive either a LMWH or a placebo for six weeks, each with concomitant chemotherapy or radiotherapy. Study outcomes included mortality (at six, 12 and 24 months), major bleeding, non‐major bleeding and combined major and non‐major bleeding. Follow‐up was complete (100%). The minimum duration of follow‐up was not reported, whereas the maximum duration was 84 months. The HR and its standard error were reported. </p> <p>Lebeau and colleagues recruited 277 participants with both limited and extensive small cell lung cancer (SCLC), 78% of which had a Karnofsky Performance Scale Index &gt; 80 (<a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>). The Karnofsky Performance Scale Index ranges from zero (dead) to 100 (normal) (<a href="./references#CD006652-bbs2-0161" title="KarnofskyD . The use of nitrogen mustard in the palliative treatment of cancer. Cancer1948;1:634-56.">Karnofsky 1948</a>). Participants were randomized to receive either a prophylactic dose of UFH for five weeks or no intervention, in combination with chemotherapy. The study outcomes were mortality (at 12, 24 and 36 months) and bleeding. Follow‐up was complete (100%). The minimum duration of follow‐up was not reported. The maximum duration of follow‐up was 59 months. HRs were estimated from published survival curves, assuming all participants were followed up for 59 months. </p> <p>Lecumberri and colleagues recruited 38 participants diagnosed with limited SCLC in a multicenter, open‐label study (<a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>). Participants were randomized to receive standard chemoradiotherapy or the same therapy plus bemiparin for a maximum of 26 weeks. The study outcomes included all‐cause mortality, incidence of VTE, major and minor bleeding, and thrombocytopenia. All outcomes were assessed at 18 months. Follow‐up was complete (100%). </p> <p>Macbeth and colleagues recruited 2202 participants diagnosed with lung cancer (<a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>). Participants were on standard anticancer treatment and randomized to subcutaneous dalteparin or no anticoagulation. The study outcomes included overall survival and bleeding. The median duration of follow‐up was 23.1 months. </p> <p>Maraveyas and colleagues recruited 123 participants with non‐resectable, recurrent or metastatic pancreatic adenocarcinoma, Karnofsky performance status (KPS) of 60 to 100, and estimated life expectancy of more than 12 weeks (<a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>). Participants were randomized to receive either subcutaneous dalteparin or placebo. The study outcomes included mortality, all‐type VTE, DVT, and PE. Data from a range of 55 to 62 participants were used for different outcome assessments. All outcomes were assessed at 12 weeks and one year follow‐up. </p> <p>Pelzer and colleagues recruited 312 chemotherapy‐naive participants with advanced pancreatic cancer (<a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>). Participants were randomized to receive or not to receive additional LMWH (enoxaparin) starting simultaneously with palliative systemic chemotherapy. Study outcomes included overall survival, symptomatic VTE, asymptomatic subclinical DVT and major bleeding. Follow‐up for overall survival was about 95.7% in the intervention group and 93.4% in the control group. The median duration of follow‐up was 30.4 weeks. </p> <p>Perry and colleagues recruited 186 participants with newly diagnosed malignant glioma (<a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>). Participants were randomized to receive a prophylactic dose of LMWH (dalteparin) or placebo. Study outcomes included objectively documented symptomatic DVT or PE (primary outcome), bleeding (major and all bleeding), quality of life and death. The duration of follow‐up was 12 months. </p> <p>Sideras and colleagues recruited 141 participants with different types of advanced cancer and a minimum life expectancy of 12 weeks and ECOG state zero to two (<a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>). Participants were randomized either to a prophylactic dose of a LMWH (dalteparin) or to placebo or no intervention. Study outcomes included overall survival (at 12, 24 and 36 months), VTE and major bleeding. Follow‐up data were available for 138 participants (98%). The minimum duration of follow‐up was not reported, whereas the maximum duration of follow‐up was 24 months. The authors supplied us with unpublished data, giving the HR and its standard error. </p> <p>Vadhan‐Raj and colleagues recruited 75 participants with metastatic or locally advanced pancreatic cancer (<a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a>). Participants were randomized to receive dalteparin 5000 U SQ daily for 16 weeks during chemotherapy or chemotherapy alone. Assessed outcomes were VTE, DVT and PE. Participants were followed‐up for 16 weeks. The study reported complete follow up. </p> <p>van Doormaal and colleagues recruited 503 participants with prostate carcinoma, NSCLC, or with a locally advanced pancreatic cancer (<a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>). Participants were randomized to receive either subcutaneous nadroparin or no nadroparin. The median duration of follow‐up was 10.5 months in the nadroparin group and 10.4 months in the control group. The study outcomes included mortality (at one, two and three years versus at five, 10, 15, 20, 25, 30, 35, 40 months), PE, DVT, major bleeding and minor bleeding. The percentage of participants lost to follow‐up was 0.8% and 3.5% from the nadroparin group and the control group respectively. </p> <p>Weber and colleagues recruited 20 participants with advanced cancer and an estimated life expectancy of less than six months (<a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>). Participants were randomized to receive either a prophylactic dose of LMWH (nadroparin) or no treatment, each with concomitant anticancer treatment. Study outcomes included mortality, VTE (including PE and DVT), minor and major bleeding, and thrombocytopenia. Follow‐up was complete (100%). The minimum duration of follow‐up was reported as three months for mortality, whereas the maximum was 18 months for all outcomes. </p> <p>Zwicker and colleagues recruited 34 participants with advanced cancer and high tissue factor‐bearing microparticles (<a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>). Participants were randomized to subcutaneous enoxaparin or observation. The study outcomes included incidence of symptomatic VTE for a follow‐up duration of two months. The trial was originally designed as a phase III, then re‐adapted to a phase II randomized clinical trial. </p> </section> <section id="CD006652-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded 99 studies (130 reports) from this review for the following reasons: not population of interest (hospitalized): n = 11; not population of interest (surgical): n = 29; not population of interest (patients with central venous catheter (CVC)): n = 7; not population of interest (patients with VTE): n = 18; not population of interest (no participants with cancer): n = 2; not intervention of interest (oral): n = 9; not intervention of interest (aspirin): n = 7; not intervention of interest (different route of administration): n=4; not comparison of interest: n = 7; not design of interest: n = 33; not outcomes of interest: n = 3. </p> </section> </section> <section id="CD006652-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>The judgments for the risk of bias are summarized in <a href="#CD006652-fig-0002">Figure 2</a> and <a href="#CD006652-fig-0003">Figure 3</a>, respectively. </p> <div class="figure" id="CD006652-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006652-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006652-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006652-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006652-sec-0051"> <h4 class="title">Allocation</h4> <p>We judged allocation to be adequately concealed in 13 of the 19 studies (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>), and not concealed in two studies (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>). Four studies did not report on allocation concealment (<a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a><a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>). </p> </section> <section id="CD006652-sec-0052"> <h4 class="title">Blinding</h4> <p><b>Blinding of participants and personnel (performance bias)</b> </p> <p>We judged participants and personnel to be definitely blinded in three studies (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a> and probably blinded in four studies (<a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>. We judged nine studies as definitely not blinded (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>) and three as probably not blinded (<a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a><a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>. </p> <p><b>Blinding of outcome assessment (detection bias)</b> </p> <p>We judged outcome assessors to be definitely blinded in two studies (<a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a> and probably blinded in nine studies (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>. We judged four studies as definitely not blinded due to their open‐label design (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>) and four as probably not blinded. (<a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a><a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>. However, we judged risk of bias in relation to detection bias as low when reporting on objective outcomes (for all 19 studies) and high when reporting on patient‐reported subjective outcomes (for two studies <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>). </p> </section> <section id="CD006652-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>Eight studies reported a complete follow‐up rate (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>;<a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a>; <a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>. </p> <p>Agnelli and colleagues reported an approximate 90% follow‐up rate in the PROTECHT trial (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>). In the SAVE‐ONCO trial, follow‐up data were reported per outcome as follows: for mortality and VTE outcomes, approximately 99% in both the intervention and control groups; for bleeding outcome, 88% in the intervention group and 95% in the control group (<a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>). </p> <p>Kakkar and colleagues reported an approximate 97% follow‐up rate in both the intervention and contro groups (<a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>). Pelzer and colleagues reported a 95% follow‐up rate in the intervention group and 93% in the control group for the outcome overall survival (<a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>). Sideras and colleagues reported a 98% follow‐up rate (<a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>). van Doormaal and colleagues reported a 97.85% follow‐up rate (<a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>). Macbeth and colleagues reported a 94% follow‐up rate in the intervention group and 97% in the control group (<a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>). </p> <p>Only one study reported follow‐up data per outcome and not per participant (<a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>). The follow‐up rates for the outcomes overall survival, VTE incidence, and toxicity ranged between 93% and 98%. </p> <p>In both studies by Haas and colleagues, it is not reported whether participants not included in the intention‐to‐treat (ITT) analyses were followed up (<a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>). All participants in the intervention group and 99% of participants in the control group were included in the analysis for TOPIC 1, whereas 98% in the intervention group and 97% in the control group were included for TOPIC 2. </p> <p>In the study by Perry and colleagues, it is not reported whether participants were followed up among those that did not receive first dose, withdrew consent, or discontinued treatment (<a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>). We judged the risk of attrition bias as high since those participants represent 37% of the intervention group and 53% of the control group. </p> </section> <section id="CD006652-sec-0054"> <h4 class="title">Selective reporting</h4> <p>The outcomes listed in the methods section were reported in the results section for 13 studies (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>). Seven studies are registered in ClinicalTrials.gov (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>). One study is registered in the ISRCTN registry (<a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>). </p> <p>One study reported on all outcomes except for two listed in the methods section (quality of life and cognition assessment) (<a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>). The outcomes of interest were all reported but were not listed in the methods section for one study (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>). </p> <p>One study had a published protocol and reported on all outcomes listed in the protocol (<a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>). One study that also had a published protocol reported on all outcomes listed in the protocol except for four that will be reported elsewhere (health economics, health‐related quality of life, dyspnea and biomarker studies) (<a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>). </p> <p>Selective reporting bias was unclear in the study published as an abstract (<a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a>). </p> </section> <section id="CD006652-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>We questioned whether in the study by Agnelli and colleagues the follow‐up time "occurring between randomization and 3 days after the last injection of the study drug" could have potentially led to differential follow‐up time between the two groups (<a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>). However, the authors report that "the duration of treatment was similar in the two study groups, with a median of approximately 3.5 months". </p> <p>Klerk and colleagues reported that "chemotherapy was more frequently administered during the period of study treatment in participants receiving placebo, whereas radiotherapy was more frequently given to participants receiving nadroparin"; thus 25% of the nadroparin group and 34% of the placebo group received chemotherapy; 32% of the nadroparin group and 18% of the placebo group received radiotherapy. Having different co‐interventions between the two groups might lead to performance bias (<a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>). </p> <p>Three studies were stopped early due to insufficient accrual (<a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>). </p> <p>We judged that in the study by Lebeau and colleagues participants received similar co‐interventions although brain and thoracic irradiation depended on response to treatment. In that study, 11% and 7%, respectively of participants randomized to heparin and control groups received radiotherapy (<a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>). </p> <p>In the study by Pelzer and colleagues, the related abstracts published in 2005 and 2007 reported a target recruitment of 540 patients whereas 312 patients were recruited into the trial (<a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>). </p> <p>The study by Zwicker and colleagues was originally designed as a phase III randomized clinical trial then re‐adapted to a phase II trial. Also, the trial is described as underpowered (<a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>). </p> </section> </section> <section id="CD006652-sec-0056"> <h3 class="title" id="CD006652-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD006652-tbl-0001"><b>Summary of findings 1</b> Heparin prophylaxis compared with no prophylaxis in ambulatory patients with cancer without VTE receiving systemic therapy</a> </p> <section id="CD006652-sec-0057"> <h4 class="title">All‐cause mortality</h4> <section id="CD006652-sec-0058"> <h5 class="title">All‐cause mortality at 12 months</h5> <p>Meta‐analysis of the 18 randomized controlled trials (RCTs), including 9575 participants, found that the use of heparin compared to no heparin has no effect on mortality rates at 12 months: risk ratio (RR) 0.98; 95% confidence interval (CI) 0.93 to 1.03; risk difference (RD) 10 fewer per 1000; 95% CI 35 fewer to 15 more (see <a href="./references#CD006652-fig-0006" title="">Analysis 1.1</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) is moderate (I<sup>2</sup> = 31%). The inverted funnel plot for the primary outcome of mortality at one year did not suggest publication bias, but there were relatively few trials to permit an accurate assessment (<a href="#CD006652-fig-0004">Figure 4</a>). The certainty of evidence was moderate due to imprecision (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). <a href="./appendices#CD006652-sec-0084">Appendix 6</a> includes the GRADE Evidence Profile (a more detailed version of the <a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD006652-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.1 Mortality at 12 months‐ Main analysis." data-id="CD006652-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.1 Mortality at 12 months‐ Main analysis. </p> </div> </div> </div> <p>In a subgroup analysis of participants with lung cancer (either SCLC or NSCLC) (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>), versus other types of cancer (that is neither SCLC or NSCLC) (<a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>), the test for subgroup difference was not statistically significant (P value = 0.47). </p> <p>In a subgroup analysis of participants with advanced cancer (including participants with extensive SCLC) (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>; <a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>), versus participants with non‐advanced cancer (including participants with limited SCLC) (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>), the test for subgroup effect was not statistically significant (P value = 0.56). </p> </section> <section id="CD006652-sec-0059"> <h5 class="title">All‐cause mortality at 24 months</h5> <p>In a meta‐analysis of 14 RCTs, including 5229 participants, we found that heparin compared to no heparin has no effect on mortality rates at 24 months: RR 0.99; 95% CI 0.96 to 1.01; RD 8 fewer per 1000; 95% CI 31 fewer to 8 more (see <a href="./references#CD006652-fig-0009" title="">Analysis 1.4</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) is moderate (I<sup>2</sup> = 27%). The certainty of evidence was moderate due to imprecision (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> <p>In a subgroup analysis of participants with advanced cancer (including participants with extensive SCLC) (<a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>), versus participants with non‐advanced cancer (including participants with limited SCLC) (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>; <a href="./references#CD006652-bbs2-0012" title="MaraveyasA , WatersJ , RoyR , FyfeD , PropperD , LoftsF , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer2012;48(9):1283-92. MaraveyasA , WatersJ , RoyR , PropperD , FyfeD , LoftsF , et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research2010;125:S161. MaraveyasAJ , WatersR , RoyD , PropperD , FyfeF , LoftsE , et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer2009;Supplements 7(2):362. ">Maraveyas 2012 (FRAGEM)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>), the test for subgroup effect was not statistically significant (P value = 0.97) </p> </section> <section id="CD006652-sec-0060"> <h5 class="title">All‐cause mortality ‐ time‐to‐event analysis</h5> <p>Fifteen studies, including 8388 participants, reported data allowing their inclusion in the time‐to‐event meta‐analysis. Meta‐analysis indicated that heparin compared to no heparin has no effect on reduction in the risk of death (hazard ratio (HR) 0.93; 95% CI 0.84 to 1.03) (see <a href="./references#CD006652-fig-0011" title="">Analysis 1.6</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) may represent moderate heterogeneity (I<sup>2</sup> = 64%). </p> </section> </section> <section id="CD006652-sec-0061"> <h4 class="title">Symptomatic venous thromboembolism (VTE)</h4> <p>Meta‐analysis of 16 RCTs, including 9036 participants, found that heparin reduces the risk of symptomatic VTE compared to no heparin: RR 0.56; 95% CI 0.47 to 0.68; RD 30 fewer per 1000; 36 fewer to 22 fewer (see <a href="./references#CD006652-fig-0012" title="">Analysis 1.7</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) is not important (I<sup>2</sup> = 0%). Results did not change in a sensitivity analysis including the study published as abstract (<a href="./references#CD006652-bbs2-0016" title="Vadhan-RajS , ZhouX , VaradhacharyGR , MilindJ , FogelmanD , ShroffR , et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood2013;122(21):580. ">Vadhan‐Raj 2013</a>): RR 0.56, 95% CI 0.46 to 0.67. Since the primary meta‐analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta‐analyses using the a priori plausible assumptions detailed in the <a href="#CD006652-sec-0015">Methods</a> section. The effect estimate remained significant across all four stringent assumptions (<a href="./appendices#CD006652-sec-0085">Appendix 7</a>). <a href="./references#CD006652-fig-0014" title="">Analysis 1.9</a> and <a href="./references#CD006652-fig-0015" title="">Analysis 1.10</a> respectively show the separate analyses for PE and symptomatic DVT. The inverted funnel plot for symptomatic VTE did not suggest publication bias, but there were relatively few trials to permit an accurate assessment (<a href="#CD006652-fig-0005">Figure 5</a>). The certainty of evidence was high (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD006652-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.7 Symptomatic VTE‐ Main analysis." data-id="CD006652-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.7 Symptomatic VTE‐ Main analysis. </p> </div> </div> </div> <p>In a subgroup analysis of participants with lung cancer (either SCLC or NSCLC), (<a href="./references#CD006652-bbs2-0001" title="AgnelliG , GussoniG , BianchiniC , VersoM , MandalàM , Cavanna L et al, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology2009;10(10):943-9. AgnelliG , GussoniG , BianchiniC , VersoM , TonatoM . A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood2008;112:6. AgnelliG , TonatoM . Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer2009;17:857-1039. BarniS , LabiancaR , AgnelliG , BonizzoniE , MandalàM , VersoM , et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer2011;19(Suppl 2):S206, 415. BarniS , LabiancaR , AgnelliG , BonizzoniE , VersoM , MandalàM , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine2011;9(179):1-7. ">Agnelli 2009 (PROTECHT)</a>; <a href="./references#CD006652-bbs2-0002" title="AgnelliG , GeorgeD , FisherWD , KakkarAK , LassenMR , MismettiP , et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer2011;47:S222. AgnelliG , GeorgeDJ , FisherW , KakkarAK , LassenMR , MismettiP , et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology2011;29:LBA9014. AgnelliG , GeorgeDJ , KakkarAK , FisherW , LassenMR , MismettiP , et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine2012;366(7):601-9. GeorgeD , AgnelliG , FisherW , KakkarA , LassenMR , MismettiP , et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood2011;118(21):96. ">Agnelli 2012 (SAVE‐ONCO)</a>; <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a><a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>) versus participants with any type of cancer (that is neither SCLC or NSCLC), (<a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>; <a href="./references#CD006652-bbs2-0007" title="KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.0092017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]KhoranaAA , FrancisCW , KudererN , CarrierM , OrtelTL , WunT , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood2015;126(23):427. ">Khorana 2017 (PHACS)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0017" title="BullerHR , PrinsMH . Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis2009;7:1203. vanDoormaalFF , Di NisioM , OttenHM , RichelDJ , PrinsM , BullerHR . Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology2011;29:2071-6. ">van Doormaal 2011 (INPACT)</a>; <a href="./references#CD006652-bbs2-0019" title="Zwicker, J, H A Liebman, K A Bauer, T Caughey, R Rosovsky, S Mantha, C M Kessler et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis2013;11:6. ZwickerJI , LiebmanHA , BauerKA , CaugheyT , CampigottoF , RosovskyR , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). British Jjournal of Haematology2013;160(4):530-7. ">Zwicker 2013 (MICRO TEC)</a>) the test for subgroup effect was not statistically significant (P value 0.21). </p> </section> <section id="CD006652-sec-0062"> <h4 class="title">Major bleeding</h4> <p>Meta‐analysis of 18 RCTs, including 9592 participants, showed that heparin likely increases the risk of major bleeding compared to no heparin: RR 1.30; 95% CI 0.94 to 1.79; RD 4 more per 1000; 95% CI 1 fewer to 11 more) (see <a href="./references#CD006652-fig-0016" title="">Analysis 1.11</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) may represent no heterogeneity (I<sup>2</sup> = 0%). The certainty of evidence was moderate due to imprecision (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> <p>In a subgroup analysis of participants with lung cancer (either SCLC or NSCL) ( <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0005" title="HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. ">Haas 2012 (TOPIC 2)</a>; <a href="./references#CD006652-bbs2-0009" title='LebeauB , ChastangC , BrechotJM , CapronF , DautzenbergB , DelaisementsC , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer1994;74(1):38-45. '>Lebeau 1994</a>; <a href="./references#CD006652-bbs2-0010" title="LecumberriR , López VivancoG , FontA , González BillalabeitiaE , GúrpideA , Gómez CodinaJ , et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research2013;132(6):666-70. LecumberriR , MassutiB , López VivancoG , FontA , González BillalabeitiaE , RochaE , on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. In: 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. Vol. 125. 2010:S161–5. MassutiB , LecumberriR , Lopez VivancoGM , FontA , Gonzalez-BillalabeitiaE , Marti-CiriquianJL , et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings2012;30(15):7095. MassutiB , Lopez-VivancoG , FontA , LecumberriR , Gonzalez BillalabeitiaE , Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology2010;21:159. ">Lecumberri 2013 (ABEL)</a>; ; <a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>), versus participants with any type of cancer (that is neither SCLC or NSCLC) (<a href="./references#CD006652-bbs2-0004" title="FreundM , KakkarAK , HaasS , HeilmannL , vonTempelhoffGF , BromJ , et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood2003;102(11):210A. GatzemeierU , FreundM , HaasS , KakkarA , ZatloukaiP , KelbelC , et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer2005;49:S56. HaasSK , FreundM , HeigenerD , HeilmannL , Kemkes-MatthesB , vonTempelhoffGF , et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis2012;18(2):159-65. HaasSK , KakkarAK , Kemkes-MatthesB , FreundM , GatzemeierU , HeilmannL , et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis &amp; Haemostasis2005;3(1):OR059. ">Haas 2012 (TOPIC 1)</a>; <a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0014" title="PerryJR , JulianJA , LaperriereNJ , GeertsW , AgnelliG , RogersLR , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis2010;8(9):1959–65. PerryJR , RogersL , LaperriereN , JulianJ , GeertsW , AgnelliG , et al, for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology2007;25:77s (Abstract 2011). ">Perry 2010 (PRODIGE)</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>), the test for subgroup effect was not statistically significant (P value = 0.61). </p> </section> <section id="CD006652-sec-0063"> <h4 class="title">Minor bleeding</h4> <p>Meta‐analysis of 16 RCTs, including 9245 participants, found that heparin causes an increase in the risk of minor bleeding compared to no heparin: RR 1.70; 95% CI 1.13 to 2.55; RD 17 more per 1000; 3 more to 37 more) (see <a href="./references#CD006652-fig-0018" title="">Analysis 1.13</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) may represent moderate heterogeneity (I<sup>2</sup> = 53%). Since the primary meta‐analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta‐analyses using the a priori plausible assumptions detailed in the <a href="#CD006652-sec-0015">Methods</a> section. The effect estimate did not lose significance across all four stringent assumptions (<a href="./appendices#CD006652-sec-0085">Appendix 7</a>). The certainty of evidence was high (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD006652-sec-0064"> <h4 class="title">Thrombocytopenia</h4> <p>Meta‐analysis of 12 RCTs, including 5832 participants, failed to show or to exclude a beneficial or detrimental effect of heparin on the risk of thrombocytopenia compared to no heparin (RR 0.69; 95% CI 0.37 to 1.27; RD 33 fewer per 1000; 95% CI 66 fewer to 28 more) (see <a href="./references#CD006652-fig-0019" title="">Analysis 1.14</a>). The I<sup>2</sup> value indicates that the percentage of the variability in effect estimates that is due to heterogeneity rather than chance may represent high heterogeneity (I<sup>2</sup> = 83%). The certainty of evidence was moderate due to imprecision (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD006652-sec-0065"> <h4 class="title">Health‐related quality of life</h4> <p>Two studies assessed quality of life, one using the Uniscale and the Symptom Distress Scale (SDS) (<a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>), the other using the Hospital Anxiety and Depression Score and EQ‐5D (<a href="./references#CD006652-bbs2-0011" title="GriffithsGO , BurnsS , NobleSI , MacbethFR , CohenD , MaughanTS . FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer2009;9(1):1. MacbethF , NobleS , EvansJ , AhmedS , CohenD , HoodK , et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology2016;34(5):488-94. MacbethF , NobleS , GriffithsG , ChowdhuryR , RolfeC , HoodK , et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology2013;8:S243. NobleS , RobbinsA , AlikhanR , HoodK , MacbethF . Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis2015;13:143. ">Macbeth 2016 (FRAGMATIC)</a>). Both studies concluded that the scores for the two scales were similar for the two study groups, both at baseline and at follow‐up. The certainty of evidence was moderate due to risk of bias (<a href="./full#CD006652-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD006652-sec-0066"> <h4 class="title">Sensitivity analyses</h4> <p>The sensitivity analysis excluding the one study at high risk of bias, <a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>, from the analyses did not change the results significantly. We have presented above the sensitivity meta‐analyses to assess the risk of bias associated with missing participant data. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006652-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006652-sec-0067"></div> <section id="CD006652-sec-0068"> <h3 class="title" id="CD006652-sec-0068">Summary of main results</h3> <p>Parenteral anticoagulation (with either unfractionated heparin or low molecular weight heparin (LMWH)) appears to have no effect on mortality in patients with cancer, who have no therapeutic or prophylactic indication for anticoagulation. While parenteral anticoagulation reduces venous thromboembolism (VTE), it likely increases major bleeding and minor bleeding. We did not identify any study using fondaparinux as an anticoagulant. </p> </section> <section id="CD006652-sec-0069"> <h3 class="title" id="CD006652-sec-0069">Overall completeness and applicability of evidence</h3> <p>The included studies recruited patients with a variety of cancer types and stages, which should increase the applicability of the results. The results apply best to LMWH, given that only one study evaluated unfractionated heparin. Unfortunately, not enough data were available to evaluate the impact of the intervention on bleeding outcomes or on quality of life. The latter outcome is important given the potential burden of daily subcutaneous injections. </p> <p>As mentioned above, we identified three eligible studies for which we were not able to obtain the necessary data from the authors. <a href="./references#CD006652-bbs2-0139" title="ChazouilleresO , PouponR , GatineausaillantG , RoulotD , BarbareJC , LabadieH , et al. Beneficial effect of low molecular weight heparin (fraxiparin) on short term mortality in patients with unresectable hepatocellular carcinoma (HCC). A randomized study. Gastroenterology1994;106(4):A874.">Chazouilleres 1994</a> recruited 51 participants with unresectable hepatocellular carcinoma and reported a lower short‐term mortality rate with LMWH. <a href="./references#CD006652-bbs2-0170" title="SalatC , BreitruckH , ReinhardtB , HillerE . Thromboprophylaxis with low molecular weight heparin (LMWH) and conventional low dose heparin in patients with malignant diseases. Blut1990;61(2-3):142.">Salat 1990</a> did not report on mortality outcome. Vadhan‐Raj 2013a randomized 75 participants with metastatic or locally advanced pancreatic cancer and reported a trend towards a reduction in VTE. </p> </section> <section id="CD006652-sec-0070"> <h3 class="title" id="CD006652-sec-0070">Quality of the evidence</h3> <p>Our systematic approach to searching, study selection and data extraction should have minimized the likelihood of missing relevant studies. The certainty of evidence was high for symptomatic VTE and minor bleeding, moderate for mortality, major bleeding and quality of life. </p> </section> <section id="CD006652-sec-0071"> <h3 class="title" id="CD006652-sec-0071">Potential biases in the review process</h3> <p>The inclusion of different types of cancer in the same study precluded us from conducting the subgroup analyses to explore effect modifiers such as type and stage of cancer. The interpretation of findings is also limited by not including data from the trials published as abstracts only. Also, for two studies we had to calculate the number of mortality events at 12 and 24 months from the survival curves (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0006" title="KakkarAK , LevineMN , KadziolaZ , LemoineNR , LowV , PatelHK , et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology2004;22(10):1944-8. ">Kakkar 2004 (FAMOUS)</a>). Also, there might be potential bias associated with multiple testing in the planned meta‐analyses and currently there are no plans to adjust meta‐analyses for multiple testing. </p> </section> <section id="CD006652-sec-0072"> <h3 class="title" id="CD006652-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>A recent review by Che and colleagues assessed the effect of LMWH compared with no heparin in patients with cancer with no history of VTE (<a href="./references#CD006652-bbs2-0140" title="CheDH , CaoJY , ShangLH , ManYC , YuY . The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. European Journal of Internal Medicine2013;24:433-9.">Che 2013</a>). Similar to our findings, the review found that LMWH significantly reduced the risk of VTE and increased the risk of bleeding. Moreover, this study did not focus on the type of intervention or type of participants, for example the pooled participants included patients being started on thromboprophylaxis due the placement of a central venous catheter (CVC), or in the perioperative setting. Our review eligibility criteria focused on parenteral anticoagulation in ambulatory patients with cancer, i.e. reducing clinical heterogeneity. </p> <p>Another Cochrane systematic review conducted by Di Nisio and colleagues assessed the efficacy and safety of primary thromboprophylaxis in ambulatory patients with cancer receiving chemotherapy (<a href="./references#CD006652-bbs2-0149" title="Di NisioM , PorrecaE , CandeloroM , De TursiM , RussiI , RutjesAWS . Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD008500. [DOI: 10.1002/14651858.CD008500.pub4]">Di Nisio 2016</a>). The review found that LMWH, when compared with inactive control, significantly reduced the incidence of symptomatic VTE, whereas there was no statistically significant effects on major bleeding, asymptomatic VTE, minor bleeding, one‐year mortality, symptomatic arterial thromboembolism, superficial thrombophlebitis or serious adverse events. The authors included various interventions for both prophylactic and therapeutic purposes in different populations. The interventions included parenteral anticoagulants (LMWH, unfractionated heparin), oral agents (Vitamin K antagonists (VKA), direct oral anticoagulants (DOAC), aspirin, antithrombin), and placebo. The populations included patients without VTE, with VTE, with multiple myeloma, and pediatrics. We tackled most of these comparisons in separate Cochrane reviews (<a href="./references#CD006652-bbs2-0130" title="AklEA , KahaleL , NeumannI , BarbaM , SperatiF , TerrenatoI , et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD006649. [DOI: 10.1002/14651858.CD006649.pub6]">Akl 2014 (initial)</a>; <a href="./references#CD006652-bbs2-0131" title="AklEA , KahaleLA , BarbaM , NeumannI , LabediN , TerrenatoI , et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD006650. [DOI: 10.1002/14651858.CD006650.pub4]">Akl 2014 (long‐term)</a>; <a href="./references#CD006652-bbs2-0132" title="AklEA , KahaleL , TerrenatoI , NeumannI , YosuicoVE , BarbaM , et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD006466. [DOI: 10.1002/14651858.CD006466.pub5]">Akl 2014 (oral)</a>) </p> <p>Another recent publication by Phan and colleagues, studying the efficacy of heparin‐based medications for prevention of VTE, found a significant reduction in VTE with an odds ratio (OR) of 0.56 (95% confidence interval (CI) 0.45 to 0.71) (<a href="./references#CD006652-bbs2-0166" title="PhanM , JohnS , CasanegraAI , RathbunS , MansfieldA , StonerJA , et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. Journal of Thrombosis and Thrombolysis2014;38:241-9.">Phan 2014</a>). However, that review had limitations in comparison to ours. That review did not include four studies we deemed to be eligible (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0013" title="PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. In: Onkologie - DGHO meeting. Vol. 580. October 2009:Abstract. PelzerU , HilbigA , StielerJ , RollL , RiessH , DorkenB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie2005;28(Suppl 3):54 (Abstract 151). PelzerU , HilbigA , StielerJ , RollL , StauchM , OpitzB , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings2006;24(18):4110. PelzerU , HilbigA , StielerJM , BahraM , SinnM , GebauerB , et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer2014;14:204. PelzerU , OettleH , StauchM , OpitzB , StielerJ , ScholtenT , RiessT . Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. In: XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. PelzerU , OpitzB , DeutschinoffG , StauchM , ReitzigPC , HahnfeldS , et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology2015;33(18):2028-34. RiessH , PelzerU , DeutschinoffG , OpitzB , StauchM , ReitzigP , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings2009;27(18S):LBA4506. RiessH , PelzerU , HilbigA , StielerJ , OpitzB , ScholtenT , et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008;8:361. RiessH , PelzerU , OpitzB , StauchM , ReitzigP , HahnfeldS , et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference2010;28(15 suppl):4033. RiessHB , PelzerU , OpitzB , HilbigA , StrauchM , HahnfeldS , et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis2009;7(Suppl. 2):1–1204. ">Pelzer 2015 (CONKO‐004)</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>). The reported reason for not including two of these studies was that VTE was not assessed (<a href="./references#CD006652-bbs2-0003" title="AltinbasM , CoskunHS , ErO , OzkanM , EserB , UnalA , et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). In: Proceedings of the American Society of Clinical Oncology. Vol. 20. 2001:1280. AltinbasM , CoskunHS , OzkanM , EserB , UnalA , CetinM , et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis2004;2:1266-71. AltinbasM , OzkanM , CoskunHS , ErO , EserB , UnalA , et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology2000;11:117. ">Altinbas 2004</a>; <a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>). There was no reference to the two other studies (<a href="./references#CD006652-bbs2-0015" title="SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , DakhilSR , et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology2005;23(16):775S. SiderasK , SchaeferPL , OkunoSH , SloanJA , KuttehL , FitchTR , et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings2006;81(6):758-67. ">Sideras 2006</a>; <a href="./references#CD006652-bbs2-0018" title="WeberC , MerminodT , HerrmannFR , ZulianGB . Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008;16(7):847-52. ">Weber 2008</a>). Secondly, <a href="./references#CD006652-bbs2-0166" title="PhanM , JohnS , CasanegraAI , RathbunS , MansfieldA , StonerJA , et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. Journal of Thrombosis and Thrombolysis2014;38:241-9.">Phan 2014</a> included in the review the <a href="./references#CD006652-bbs2-0177" title="YoungAM , BillinghamLJ , BegumG , KerrDJ , HughesAI , ReaDW , et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet2009;373(9663):567-74.">Young 2009</a> trial, assessing anticoagulation in patients with a CVC. This introduced increased clinical heterogeneity. We have included that trial in a separate Cochrane review evaluating prophylaxis for catheter‐related thrombosis (<a href="./references#CD006652-bbs2-0129" title="AklEA , RamlyEP , KahaleLA , YosuicoVED , BarbaM , SperatiF , et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD006468. [DOI: 10.1002/14651858.CD006468.pub5]">Akl 2014 (CVC)</a>). Unlike the review conducted by <a href="./references#CD006652-bbs2-0166" title="PhanM , JohnS , CasanegraAI , RathbunS , MansfieldA , StonerJA , et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. Journal of Thrombosis and Thrombolysis2014;38:241-9.">Phan 2014</a>, we did not include in the VTE meta‐analysis the trial conducted by Klerk and colleagues (<a href="./references#CD006652-bbs2-0008" title="KlerkCP , SmorenburgSM , OttenHM , LensingAW , PrinsMH , PiovellaF , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology2005;23(10):2130-5. KlerkCPW , SmorenburgS , OttenHM , RichelD , TienhovenG , LensingA , et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology : ASCO annual meeting proceedings2004;22:729. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis &amp; Haemostasis2003;1(Suppl 1):OC195. KlerkCPW , SmorenburgSM , OttenJMMB , BullerHR . Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis2003;33(Suppl 1):75. ">Klerk 2005 (MALT)</a>) because the number of VTE events reported pertains to participants who discontinued the study drug prematurely because they developed VTE; the paper does not report the total number of VTE observed in the trial. Moreover, <a href="./references#CD006652-bbs2-0166" title="PhanM , JohnS , CasanegraAI , RathbunS , MansfieldA , StonerJA , et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. Journal of Thrombosis and Thrombolysis2014;38:241-9.">Phan 2014</a> focused solely on VTE and did not assess other patient‐important outcomes, such as mortality. </p> <p>Similary, another systematic review conducted by Ben Aharon and colleagues assessing the efficacy and safety of primary thromboprophylaxis with LMWH in ambulatory participants with solid malignancies (<a href="./references#CD006652-bbs2-0138" title="Ben-AharonI , StemmerSM , LeiboviciL , ShpilbergO , SulkesA , Gafter-GviliA . Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies–systematic review and meta-analysis. Acta Oncologica2014;53(9):1230-7.">Ben‐Aharon 2014</a>) found that primary prophylaxis with LMWH reduced symptomatic VTE (RR and the rate of PE especially in the subgroup of participants with lung and pancreatic cancers. They found no significant effect for anticoagulation on one‐year mortality or major bleeding. </p> <p>Another systematic review conducted by Zhang and colleagues assessed whether anticoagulation improves survival and VTE outcomes in participants with lung cancer exclusively with no indication for anticoagulation (<a href="./references#CD006652-bbs2-0178" title="Zhang J1, ZhangYL , MaKX , Qu JM. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax2013;68(5):442-450.">Zhang 2013</a>). Anticoagulation showed a survival benefit, prolonged life expectancy, and reduced the risk of VTE in participants with lung cancer with no indication for anticoagulants, especially for those with SCLC, whereas our review included a wider range of patients with various types of cancer. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006652-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006652-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006652-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006652-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.1 Mortality at 12 months‐ Main analysis." data-id="CD006652-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.1 Mortality at 12 months‐ Main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.7 Symptomatic VTE‐ Main analysis." data-id="CD006652-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Heparin versus placebo, outcome: 1.7 Symptomatic VTE‐ Main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 1: Mortality at 12 months‐ Main analysis" data-id="CD006652-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 1: Mortality at 12 months‐ Main analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 2: Mortality at 12 months‐ Subgroups Lung vs non‐Lung Cancer" data-id="CD006652-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 2: Mortality at 12 months‐ Subgroups Lung vs non‐Lung Cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 3: Mortality at 12 months‐ Subgroups Advanced vs non‐Advanced" data-id="CD006652-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 3: Mortality at 12 months‐ Subgroups Advanced vs non‐Advanced </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 4: Mortality at 24 months‐ Main Analysis" data-id="CD006652-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 4: Mortality at 24 months‐ Main Analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 5: Mortality at 24 months‐ Subgroups Advanced vs non‐Advanced" data-id="CD006652-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 5: Mortality at 24 months‐ Subgroups Advanced vs non‐Advanced </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 6: Mortality over duration of study" data-id="CD006652-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 6: Mortality over duration of study</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 7: Symptomatic VTE‐ Main analysis" data-id="CD006652-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 7: Symptomatic VTE‐ Main analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 8: Symptomatic VTE‐ Subgroups Lung vs non‐Lung Cancer" data-id="CD006652-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 8: Symptomatic VTE‐ Subgroups Lung vs non‐Lung Cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 9: PE" data-id="CD006652-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 9: PE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 10: Symptomatic DVT" data-id="CD006652-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 10: Symptomatic DVT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 11: Major bleeding‐ Main analysis" data-id="CD006652-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 11: Major bleeding‐ Main analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 12: Major bleeding‐ Subgroups Lung vs non‐Lung Cancer" data-id="CD006652-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 12: Major bleeding‐ Subgroups Lung vs non‐Lung Cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 13: Minor bleeding" data-id="CD006652-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 13: Minor bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006652-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/urn:x-wiley:14651858:media:CD006652:CD006652-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo, Outcome 14: Thrombocytopenia" data-id="CD006652-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_t/tCD006652-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo, Outcome 14: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/media/CDSR/CD006652/image_n/nCD006652-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006652-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin prophylaxis compared with no prophylaxis in ambulatory patients with cancer without VTE receiving systemic therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Heparin prophylaxis compared with no prophylaxis in ambulatory patients with cancer without VTE receiving systemic therapy</b> </p> <p><b>P</b>: Ambulatory patients with cancer without VTE receiving systemic therapy </p> <p><b>I</b>: Heparin prophylaxis </p> <p><b>C</b>: No prophylaxis </p> <p><b>S</b>: Outpatient </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow‐up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with No prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Heparin prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9575<br/>(18 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.93 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 fewer per 1000<br/>(35 fewer to 15 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5229<br/>(14 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.96 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>778 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(31 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9036<br/>(16 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/>(0.47 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 fewer per 1000<br/>(36 fewer to 22 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9592<br/>(18 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/>(0.94 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(1 fewer to 11 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>9245<br/>(16 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70<br/>(1.13 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 more per 1000<br/>(3 more to 37 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5832<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/>(0.37 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/>(66 fewer to 28 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life impairment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2241<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Macbeth 2016 (FRAGMATIC): " There was no difference between the two groups with respect to quality‐adjusted life years gained in the first year... No difference in overall quality of life at 6 months (P = .94) or at 12 months (P = .89)... Overall quality of life did not change significantly over the study period".Sideras 2006: "The QOL and SDS scores were similar, both at baseline and during the protocol period, in patients randomized to receive LMWH vs those not randomized to receive LMWH." </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision: Confidence interval includes values suggesting clinically significant benefit and values suggesting no effect. </p> <p><sup>2</sup> Downgraded one level due to serious imprecision: Confidence interval includes values suggesting clinically significant harm and values suggesting no effect. </p> <p><sup>3</sup> Downgraded one level due to serious imprecision: Confidence interval includes values suggesting clinically significant benefit and values suggesting harm. </p> <p><sup>4</sup> Downgraded one level due to serious risk of bias: Both studies were open‐label studies (lack of blinding may impact the patient‐reported subjective outcomes) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin prophylaxis compared with no prophylaxis in ambulatory patients with cancer without VTE receiving systemic therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006652-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assisting in the amelioration or cure of disease</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The process of hindering the clotting of blood especially by treatment with an anticoagulant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antithrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used against or tending to prevent thrombosis (clotting)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacteremia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The presence of bacteria in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central venous line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Synthetic tube that is inserted into a central (large) vein of a patient to provide temporary intravenous access for the administration of fluid, medication or nutrients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (such as swelling and pain) and that is potentially life‐threatening if dislodgment of the thrombus results in pulmonary embolism </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fibrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A white insoluble fibrous protein formed from fibrinogen by the action of thrombin, especially in the clotting of blood </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fondaparinux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anticoagulant medication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hemostatic system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The system that shortens the clotting time of blood and stops bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. Two forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impedance plethysmography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kappa statistics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A measure of degree of non‐random agreement between observers and/or measurements of a specific categorical variable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The spread of cancer cells from the initial or primary site of disease to another part of the body </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oncogene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A gene having the potential to cause a normal cell to become cancerous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Osteoporosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A condition that especially affects older women and is characterized by a decrease in bone mass with decreased density and enlargement of bone spaces producing porosity and brittleness </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parenteral nutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The practice of feeding a patient intravenously, circumventing the gut</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing, chest pain, fainting, rapid heart rate, cyanosis, shock and sometimes death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The supporting framework of an organ typically consisting of connective tissue</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A proteolytic enzyme formed from prothrombin that facilitates the clotting of blood by catalyzing conversion of fibrinogen to fibrin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistent decrease in the number of blood platelets that is often associated with hemorrhagic conditions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The formation or presence of a blood clot within a blood vessel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin K antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anticoagulant medication that is a vitamin K antagonist, which is used for anticoagulation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anticoagulant medication</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006652-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">LMWH: definitions of prophylactic and therapeutic dosages</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LMWH</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Generic name</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic dose</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic dose</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lovenox</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enoxaparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/kg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fragmin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dalteparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2500 to 5000 units once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 U/kg once daily or<br/>100 U/kg twice daily </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Innohep, Logiparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinzaparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4500 units once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 U/kg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fraxiparine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nadroparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 to 75 anti‐Xa international units/kg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 anti‐Xa int. units/kg once daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certoparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sandoparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3000 anti‐Xa international units once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">LMWH: definitions of prophylactic and therapeutic dosages</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/full#CD006652-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006652-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mortality at 12 months‐ Main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mortality at 12 months‐ Subgroups Lung vs non‐Lung Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Lung Cancer (SCLC or NSCLC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 non‐Lung Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mortality at 12 months‐ Subgroups Advanced vs non‐Advanced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Advanced cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Non‐advanced cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mortality at 24 months‐ Main Analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mortality at 24 months‐ Subgroups Advanced vs non‐Advanced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Advanced cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Non‐advanced cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mortality over duration of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Symptomatic VTE‐ Main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.47, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Symptomatic VTE‐ Subgroups Lung vs non‐Lung Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.43, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Lung Cancer (SCLC or NSCLC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.41, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Non‐lung cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.37, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.47, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Symptomatic DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.33, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Major bleeding‐ Main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.94, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Major bleeding‐ Subgroups Lung vs non‐Lung Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.02, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Lung Cancer (SCLC or NSCLC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.77, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Non‐lung cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.94, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.13, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.37, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006652.pub5/references#CD006652-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006652.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006652-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006652-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006652-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ko#CD006652-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006652-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006652-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD006652-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006652-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006652\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006652\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006652\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006652\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006652\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006652.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006652.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006652.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006652.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006652.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717766369"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006652.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717766373"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006652.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbfeb28dc936b',t:'MTc0MDcxNzc2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 